Hyporesponsiveness and its clinical implications after vaccination with polysaccharide or glycoconjugate vaccines

References

• Schuchat A, Robinson K, Wenger JD et al. Bacterial meningitis in the United States in 1995. Active Surveillance Team. N. Engl. J. Med.337(14), 970–976 (1997).
   PubMed Web of Science ®Google Scholar
• Peltola H. Burden of meningitis and other severe bacterial infections of children in Africa: implications for prevention. Clin. Infect. Dis.32(1), 64–75 (2001).
   PubMed Web of Science ®Google Scholar
• Cripps AW, Otczyk DC. Prospects for a vaccine against otitis media. Expert Rev. Vaccines5(4), 517–534 (2006).
   PubMed Web of Science ®Google Scholar
• Rudan I, Boschi-Pinto C, Biloglav Z, Mulholland K, Campbell H. Epidemiology and etiology of childhood pneumonia. Bull. World Health. Organ.86(5), 408–416 (2008).
   PubMed Web of Science ®Google Scholar
• Weller PF, Smith AL, Anderson P, Smith DH. The role of encapsulation and host age in the clearance of Haemophilus influenzae bacteremia. J. Infect. Dis.135(1), 34–41 (1997).
   Google Scholar
• Winkelstein JA, Bocchini JA Jr, Schiffman G. The role of the capsular polysaccharide in the activation of the alternative pathway by the pneumococcus. J. Immunol.116(2), 367–370 (1976).
   PubMed Web of Science ®Google Scholar
• Kugelberg E, Gollan B, Tang CM. Mechanisms in Neisseria meningitidis for resistance against complement-mediated killing. Vaccine26(Suppl. 8), 134–139 (2008).
   Google Scholar
• Anderson P, Johnston RB Jr, Smith DH. Human serum activities against Haemophilus influenzae type b. J. Clin. Invest.51(1), 31–38 (1972).
   PubMedGoogle Scholar
• Weller PF, Smith AL, Smith DH, Anderson P. Role of immunity in the clearance of bacteremia due to Haemophilus influenzae. J. Infect. Dis.138(4), 427–436 (1978).
   PubMedGoogle Scholar
• Santosham M, Reid R, Ambrosino DM et al. Prevention of Haemophilus influenzae type b infections in high-risk infants treated with bacterial polysaccharide immune globulin. N. Engl. J. Med.317(15), 923–929 (1987).
   PubMed Web of Science ®Google Scholar
• Ambrosino DM, Barrus VA, DeLange GG, Siber GR. Correlation of the Km(1) immunoglobulin allotype with anti-polysaccharide antibodies in Caucasian adults. J. Clin. Invest.78(2), 361–365 (1986).
   PubMedGoogle Scholar
• Balloch A, Licciardi PV, Russell FM, Mulholland EK, Tang ML. Infants aged 12 months can mount adequate serotype-specific IgG responses to pneumococcal polysaccharide vaccine. J. Allergy Clin. Immunol.126(2), 395–397 (2010).
   PubMedGoogle Scholar
• O’Grady KA, Lee KJ, Carlin JB et al. Increased risk of hospitalization for acute lower respiratory tract infection among Australian indigenous infants 5–23 months of age following pneumococcal vaccination: a cohort study. Clin. Infect. Dis.50(7), 970–978 (2010).
   PubMedGoogle Scholar
• Humphrey JH. Splenic macrophages: antigen presenting cells for T1–2 antigens. Immunol. Lett.11(3–4), 149–152 (1985).
   PubMedGoogle Scholar
• Timens WA. The Human Spleen. Development and Role in the Immune System. University of Groningen, The Netherlands (1985) (Thesis).
   Google Scholar
• Reingold AL, Broome CV, Hightower AW et al. Age-specific differences in duration of clinical protection after vaccination with meningococcal polysaccharide A vaccine. Lancet326(8447), 114–118 (1985).
   Google Scholar
• Vergnano S, Heath P. Neisseria meningitides serogroup A vaccines: an overview. Expert Rev. Vaccines2(4), 571–582 (2003).
   PubMedGoogle Scholar
• Ismail AA. Harris SL, Granoff DM. Serum group A anticapsular antibodies in a Sudanese population immunized with meningococcal polysaccharide vaccine during a group A epidemic. Pediatr. Infect. Dis. J.23(8), 748–755 (2004).
   PubMed Web of Science ®Google Scholar
• Koskela M, Leinonen M, Häivä VM, Timonen M, Mäkelä PH. First and second dose antibody responses to pneumococcal polysaccharide vaccine in infants. Pediatr. Infect. Dis.5(1), 45–50 (1986).
   PubMedGoogle Scholar
• Käyhty H. Difficulties in establishing a serological correlate of protection after immunization with Haemophilus influenzae conjugate vaccines. Biologicals22(4), 397–402 (1994).
   PubMed Web of Science ®Google Scholar
• Lepow ML, Barkin RM, Berkowitz CD et al. Safety and immunogenicity of Haemophilus influenzae type b polysaccharide–diphtheria toxoid conjugate vaccine (PRP-D) in infants. J. Infect. Dis.156(4), 591–596 (1987).
   PubMedGoogle Scholar
• Weinberg GA, Einhorn MS, Lenoir AA, Granoff PD, Granoff DM. Immunologic priming to capsular polysaccharide in infants immunized with Haemophilus influenzae type b polysaccharide–Neisseria meningitidis outer membrane protein conjugate vaccine. J. Pediatr.111(1), 22–27 (1987).
   PubMed Web of Science ®Google Scholar
• Granoff DM, Sheetz KE, Nahm MH, Madassery JV, Shackelford PG. Further immunologic evaluation of children who develop Haemophilus disease despite previous vaccination with type b polysaccharide vaccine. Monogr. Allergy.23, 256–268 (1988).
   PubMedGoogle Scholar
• MacDonald NE, Halperin SA, Law BJ, Forrest B, Danzig LE, Granoff DM. Induction of immunologic memory by conjugated vs plain meningococcal C polysaccharide vaccine in toddlers: a randomized controlled trial. JAMA280(19), 1685–1689 (1998).
   PubMed Web of Science ®Google Scholar
• Anderson PW, Pichichero ME, Stein EC et al. Effect of oligosaccharide chain length, exposed terminal group, and hapten loading on the antibody response of human adults and infants to vaccines consisting of Haemophilus influenzae type b capsular antigen unterminally coupled to the diphtheria protein CRM197. J. Immunol.142(7), 2464–2468 (1989).
   PubMed Web of Science ®Google Scholar
• Ambrosino DM, Sood SK, Lee MC et al. IgG1, IgG2 and IgM responses to two Haemophilus influenzae type b conjugate vaccines in young infants. Pediatr. Infect. Dis. J.11(10), 855–859 (1992).
   PubMed Web of Science ®Google Scholar
• Anttila M, Eskola J, Ahman H, Käyhty H. Avidity of IgG for Streptococcus pneumoniae type 6B and 23F polysaccharides in infants primed with pneumococcal conjugates and boosted with polysaccharide or conjugate vaccines. J. Infect. Dis.177(6), 1614–1621 (1998).
   PubMed Web of Science ®Google Scholar
• Harris SL, Finn A, Granoff DM. Disparity in functional activity between serum anticapsular antibodies induced in adults by immunization with an investigational group A and C Neisseria meningitidis–diphtheria toxoid conjugate vaccine and by a polysaccharide vaccine. Infect. Immun.71(6), 3402–3408 (2003).
   PubMedGoogle Scholar
• Lucas AH, Granoff DM. Functional differences in idiotypically defined IgG1 anti-polysaccharide antibodies elicited by vaccination with Haemophilus influenzae type B polysaccharide–protein conjugates. J. Immunol.154(8), 4195–4202 (1995).
   PubMed Web of Science ®Google Scholar
• Goldblatt D, Vaz AR, Miller E. Antibody avidity as a surrogate marker of successful priming by Haemophilus influenzae type b conjugate vaccines following infant immunization. J. Infect. Dis.177(4), 1112–1115 (1998).
   PubMed Web of Science ®Google Scholar
• Joseph H, Ryall R, Bybel M et al. Immunogenicity and immunological priming of the serogroup a portion of a bivalent meningococcal A/C conjugate vaccine in 2-year-old children. J. Infect. Dis.187(7), 1142–1146 (2003).
   PubMedGoogle Scholar
• Borrow R, Southern J, Andrews N et al. Comparison of antibody kinetics following meningococcal serogroup C conjugate vaccine between healthy adults previously vaccinated with meningococcal A/C polysaccharide vaccine and vaccine-naive controls. Vaccine19(23–24), 3043–3050 (2001).
   PubMed Web of Science ®Google Scholar
• Ekström N, Ahman H, Verho J et al. Kinetics and avidity of antibodies evoked by heptavalent pneumococcal conjugate vaccines PncCRM and PncOMPC in the Finnish Otitis Media Vaccine Trial. Infect. Immun.73(1), 369–377 (2005).
   PubMed Web of Science ®Google Scholar
• Poolman J, Kaufhold A, De Grave D, Goldblatt D. Clinical relevance of lower Hib response in DTPa-based combination vaccines. Vaccine19(17–19), 2280–2285 (2001).
   PubMed Web of Science ®Google Scholar
• Lenoir AA, Pandey JP, Granoff DM. Antibody responses of black children to Haemophilus influenzae type b polysaccharide–Neisseria meningitidis outer-membrane protein conjugate vaccine in relation to the Km(1) allotype. J. Infect. Dis.157(6), 1242–1245 (1988).
   PubMedGoogle Scholar
• Gross S, Blaiss MS, Herrod HG. Role of immunoglobulin subclasses and specific antibody determinations in the evaluation of recurrent infection in children. J. Pediatr.121(4), 516–522 (1992).
   PubMedGoogle Scholar
• Provenzano RW, Wetterlow LH, Sullivan CL. Immunization and antibody response in the newborn infant: I. Pertussis inoculation within twenty-four hours of birth. N. Engl. J. Med.273(18), 959–965 (1965).
   PubMed Web of Science ®Google Scholar
• Barrett CD, Timm EA, Molner JG, Wilner BI, Fahey MF, McLean IW. Multiple antigen for immunization against poliomyelitis, diphtheria, pertussis, and tetanus. II. Response of infants and young children to primary immunization and eighteen-month booster. Am. J. Public Health49(5), 644–655 (1959).
   PubMed Web of Science ®Google Scholar
• Halasa NB, O’Shea A, Shi JR, LaFleur BJ, Edwards KM. Poor immune responses to a birth dose of diphtheria, tetanus, and acellular pertussis vaccine. J. Pediatr.153(3), 327–332 (2008).
   PubMed Web of Science ®Google Scholar
• Lieberman JM, Greenberg DP, Wong VK et al. Effect of neonatal immunization with diphtheria and tetanus toxoids on antibody responses to Haemophilus influenzae type b conjugate vaccines. J. Pediatr.126(2), 198–205 (1995).
   PubMed Web of Science ®Google Scholar
• Dagan R, Givon-Lavi N, Greenberg D, Fritzell B, Siegrist CA. Nasopharyngeal carriage of Streptococcus pneumoniae shortly before vaccination with a pneumococcal conjugate vaccine causes serotype-specific hyporesponsiveness in early infancy. J. Infect. Dis.201(10), 1570–1579 (2010).
   PubMed Web of Science ®Google Scholar
• Granoff DM, Pollard AJ. Reconsideration of the use of meningococcal polysaccharide vaccine. Pediatr. Infect. Dis. J.26(8), 716–722 (2007).
   PubMed Web of Science ®Google Scholar
• Russell FM, Carapetis JR, Burton RL et al. Opsonophagocytic activity following a reduced dose 7-valent pneumococcal conjugate vaccine infant primary series and 23-valent pneumococcal polysaccharide vaccine at 12 months of age. Vaccine29(3), 535–544 (2011).
   PubMedGoogle Scholar
• Borrow R, Stanford E, Waight P et al. Serotype-specific immune unresponsiveness to pneumococcal conjugate vaccine following invasive pneumococcal disease. Infect. Immun.76(11), 5305–5309 (2008).
   PubMedGoogle Scholar
• Vakevainen M, Soininen A, Lucero M et al. Serotype-specific hyporesponsiveness to pneumococcal conjugate vaccine in infants carrying pneumococcus at the time of vaccination. J. Pediatr.157(5), 778–783 (2010).
   PubMed Web of Science ®Google Scholar
• Baxendale HE, Davis Z, White HN, Spellerberg MB, Stevenson FK, Goldblatt D. Immunogenetic analysis of the immune response to pneumococcal polysaccharide. Eur. J. Immunol.30(4), 1214–1223 (2000).
   PubMed Web of Science ®Google Scholar
• Mäkelä O, Mattila P, Rautonen N, Seppälä I, Eskola J, Käyhty H. Isotype concentrations of human antibodies to Haemophilus influenzae type b polysaccharide (Hib) in young adults immunized with the polysaccharide as such or conjugated to a protein (diphtheria toxoid). J. Immunol.139(6), 1999–2004 (1987).
   PubMedGoogle Scholar
• Shackelford PG, Granoff DM, Nelson SJ, Scott MG, Smith DS, Nahm MH. Subclass distribution of human antibodies to Haemophilus influenzae type b capsular polysaccharide. J. Immunol.138(2), 587–592 (1987).
   PubMed Web of Science ®Google Scholar
• O’Brien KL, Hochman M, Goldblatt D. Combined schedules of pneumococcal conjugate and polysaccharide vaccines: is hyporesponsiveness an issue? Lancet Infect. Dis.7(9), 597–606 (2007).
   PubMed Web of Science ®Google Scholar
• Meltzer U, Goldblatt D. Pneumococcal polysaccharides interact with human dendritic cells. Infect. Immun.74(3), 1890–1895 (2006).
   PubMed Web of Science ®Google Scholar
• Holmes SJ, Granoff DM. The biology of Haemophilus influenzae type b vaccination failure. J. Infect. Dis.165(Suppl. 1), 121–128 (1992).
   Google Scholar
• Käyhty H, Karanko V, Peltola H, Mäkelä PH. Serum antibodies after vaccination with Haemophilus influenzae type b capsular polysaccharide and responses to reimmunization: no evidence of immunologic tolerance or memory. Pediatrics74(5), 857–865 (1984).
   PubMed Web of Science ®Google Scholar
• Granoff DM, Gupta RK, Belshe RB, Anderson EL. Induction of immunologic refractoriness in adults by meningococcal C polysaccharide vaccination. J. Infect. Dis.178(3), 870–748 (1998).
   PubMed Web of Science ®Google Scholar
• Jokhdar H, Borrow R, Sultan A et al. Immunologic hyporesponsiveness to serogroup C but not serogroup A following repeated meningococcal A/C polysaccharide vaccination in Saudi Arabia. Clin. Diagn. Lab. Immunol.11(1), 83–88 (2004).
   PubMedGoogle Scholar
• Leach A, Twumasi PA, Kumah S et al. Induction of immunologic memory in Gambian children by vaccination in infancy with a group A plus group C meningococcal polysaccharide–protein conjugate vaccine. J. Infect. Dis.175(1), 200–204 (1997).
   PubMed Web of Science ®Google Scholar
• Keyserling H, Papa T, Koranyi K et al. Safety, immunogenicity, and immune memory of a novel meningococcal (groups A, C, Y, and W-135) polysaccharide diphtheria toxoid conjugate vaccine (MCV-4) in healthy adolescents. Arch. Pediatr. Adolesc. Med.159(10), 907–913 (2005).
   PubMed Web of Science ®Google Scholar
• Vu DM, de Boer AW, Danzig L et al. Priming for immunologic memory in adults by meningococcal group C conjugate vaccination. Clin. Vaccine Immunol.13(6), 605–610 (2006).
   PubMedGoogle Scholar
• Richmond P, Kaczmarski E, Borrow R et al. Meningococcal C polysaccharide vaccine induces immunologic hyporesponsiveness in adults that is overcome by meningococcal C conjugate vaccine. J. Infect. Dis.181(2), 761–764 (2000).
   PubMed Web of Science ®Google Scholar
• MacDonald NE, Halperin SA, Law BJ, Danzig LE, Granoff DM. Can meningococcal C conjugate vaccine overcome immune hyporesponsiveness induced by previous administration of plain polysaccharide vaccine? JAMA283(14), 1826–1827 (2000).
   PubMed Web of Science ®Google Scholar
• Southern J, Deane S, Ashton L et al. Effects of prior polysaccharide vaccination on magnitude, duration, and quality of immune responses to and safety profile of a meningococcal serogroup C tetanus toxoid conjugate vaccination in adults. Clin. Diagn. Lab. Immunol.11(6), 1100–1104 (2004).
   PubMedGoogle Scholar
• Gold R, Lepow ML, Goldschneider I, Draper TL, Gotschlich EC. Clinical evaluation of group A and group C meningococcal polysaccharide vaccines in infants. J. Clin. Invest.56(6), 1536–1547 (1975).
   PubMed Web of Science ®Google Scholar
• MacLennan J, Obaro S, Deeks J et al. Immunologic memory 5 years after meningococcal A/C conjugate vaccination in infancy. J. Infect. Dis.183(1), 97–104 (2001).
   PubMed Web of Science ®Google Scholar
• Al-Mazrou Y, Khalil M, Borrow R et al. Serologic responses to ACYW135 polysaccharide meningococcal vaccine in Saudi children under 5 years of age. Infect. Immun.73(5), 2932–2939 (2005).
   PubMed Web of Science ®Google Scholar
• Käyhty H, Karanko V, Peltola H, Sarna S, Mäkelä PH. Serum antibodies to capsular polysaccharide vaccine of group A Neisseria meningitidis followed for three years in infants and children. J. Infect. Dis.142(6), 861–868 (1980).
   PubMed Web of Science ®Google Scholar
• Borrow R, Joseph H, Andrews N et al. Reduced antibody response to revaccination with meningococcal serogroup A polysaccharide vaccine in adults. Vaccine19(9–10), 1129–1132 (2000).
   PubMedGoogle Scholar
• Næss LM, Guerin PJ, Rosenqvist E, Kristiansen LH, Caugant DA. Influence of prior vaccination with fractional doses of a tetravalent meningococcal polysaccharide vaccine on serum bactericidal antibody responses after revaccination. Presented at: 10th Meeting of the European Meningococcal Disease Society (EMGM). Manchester, UK, 17–19 June 2009.
   Google Scholar
• Borrow R. Meningococcal disease and prevention at the Hajj. Travel Med. Infect. Dis.7(4), 219–225 (2009).
   PubMed Web of Science ®Google Scholar
• Khalil M, Al-Mazrou Y, Bravo C et al. Response to quadrivalent meningococcal conjugate vaccine in Saudi Arabian children who previously received 2 doses of quadrivalent meningococcal polysaccharide vaccine before 2 years of age. Presented at: 10th Meeting of the European Meningococcal Disease Society (EMGM). Manchester, UK, 17–19 June 2009.
   Google Scholar
• Borgoño JM, McLean AA, Vella PP et al. Vaccination and revaccination with polyvalent pneumococcal polysaccharide vaccines in adults and infants. Proc. Soc. Exp. Biol. Med.157(1), 148–154 (1978).
   PubMed Web of Science ®Google Scholar
• Blum MD, Dagan R, Mendelman PM et al. A comparison of multiple regimens of pneumococcal polysaccharide-meningococcal outer membrane protein complex conjugate vaccine and pneumococcal polysaccharide vaccine in toddlers. Vaccine18(22), 2359–6723 (2000).
   PubMed Web of Science ®Google Scholar
• Mufson MA, Hughey DF, Turner CE, Schiffman G. Revaccination with pneumococcal vaccine of elderly persons 6 years after primary vaccination. Vaccine9(6), 403–407 (1991).
   PubMedGoogle Scholar
• Törling J, Hedlund J, Konradsen HB, Örtqvist Å. Revaccination with the 23-valent pneumococcal polysaccharide vaccine in middle-aged and elderly persons previously treated for pneumonia. Vaccine22(1), 96–103 (2003).
   PubMed Web of Science ®Google Scholar
• Heidelberger M, Dilapi MM, Siegel M, Walter AW. Persistence of antibodies in human subjects injected with pneumococcal polysaccharides. J. Immunol.65(5), 535–541 (1950).
   PubMed Web of Science ®Google Scholar
• Musher DM, Groover JE, Rowland JM et al. Antibody to capsular polysaccharides of Streptococcus pneumoniae: prevalence, persistence, and response to revaccination. Clin. Infect. Dis.17(1), 66–73 (1993).
   PubMed Web of Science ®Google Scholar
• Lawrence EM, Edwards KM, Schiffman G, Thompson JM, Vaughn WK, Wright PF. Pneumococcal vaccine in normal children. Primary and secondary vaccination. Am. J. Dis. Child.137(9), 846–850 (1983).
   PubMedGoogle Scholar
• Jackson LA, Benson P, Sneller VP et al. Safety of revaccination with pneumococcal polysaccharide vaccine. JAMA281(3), 243–248 (1999).
   PubMed Web of Science ®Google Scholar
• Sell SH, Wright PF, Vaughn WK, Hompson J, Schiffman G. Clinical studies of pneumococcal vaccines in infants. I. Reactogenicity and immunogenicity of two polyvalent polysaccharide vaccines. Rev. Infect. Dis.3(Suppl.), S97–S107 (1981).
   PubMedGoogle Scholar
• Russell FM, Carapetis JR, Balloch A et al. Hyporesponsiveness to re-challenge dose following pneumococcal polysaccharide at 12 months of age in a randomised controlled trial. Vaccine28(19), 3341–3349 (2010).
   PubMed Web of Science ®Google Scholar
• Poolman JT, Frasch CE, Käyhty H, Lestrate P, Madhi SA, Henckaerts I. Evaluation of pneumococcal polysaccharide immunoassays using a 22F adsorption step with serum samples from infants vaccinated with conjugate vaccines. Clin. Vaccine Immunol.17(1), 134–142 (2010).
   PubMed Web of Science ®Google Scholar
• Eskola J, Kilpi T, Palmu A et al. Efficacy of a pneumococcal conjugate vaccine against acute otitis media. N. Engl. J. Med.344(6), 403–409 (2001).
   PubMed Web of Science ®Google Scholar
• Black S, Shinefield H, Fireman B et al. Efficacy, safety and immunogenicity of heptavalent pneumococcal conjugate vaccine in children. Northern California Kaiser Permanente Vaccine Study Center Group. Pediatr. Infect. Dis. J.19(3), 187–195 (2000).
   PubMed Web of Science ®Google Scholar
• Lockhart SP, Hackell JG, Fritzell B. Pneumococcal conjugate vaccines: emerging clinical information and its implications. Expert Rev. Vaccines5(4), 553–564 (2006).
   PubMed Web of Science ®Google Scholar
• Russell FM, Licciardi PV, Balloch A et al. Safety and immunogenicity of the 23-valent pneumococcal polysaccharide vaccine at 12 months of age, following one, two, or three doses of the 7-valent pneumococcal conjugate vaccine in infancy. Vaccine28(18), 3086–3094 (2010).
   PubMed Web of Science ®Google Scholar
• Shelly MA, Jacoby H, Riley GJ, Graves BT, Pichichero M, Treanor JJ. Comparison of pneumococcal polysaccharide and CRM197-conjugated pneumococcal oligosaccharide vaccines in young and elderly adults. Infect. Immun.65(1), 242–247 (1997).
   PubMed Web of Science ®Google Scholar
• Jackson LA, Neuzil KM, Nahm MH et al. Immunogenicity of varying dosages of 7-valent pneumococcal polysaccharide–protein conjugate vaccine in seniors previously vaccinated with 23-valent pneumococcal polysaccharide vaccine. Vaccine25(20), 4029–4037 (2007).
   PubMed Web of Science ®Google Scholar
• de Roux A, Schmöle-Thoma B, Siber GR et al. Comparison of pneumococcal conjugate polysaccharide and free polysaccharide vaccines in elderly adults: conjugate vaccine elicits improved antibacterial immune responses and immunological memory. Clin. Infect. Dis.46(7), 1015–1023 (2008).
   PubMed Web of Science ®Google Scholar
• Nolan T, Lambert S, Roberton D et al. A novel combined Haemophilus influenzae type b-Neisseria meningitidis serogroups C and Y-tetanus-toxoid conjugate vaccine is immunogenic and induces immune memory when co-administered with DTPa-HBV-IPV and conjugate pneumococcal vaccines in infants. Vaccine25(51), 8487–8499 (2007).
   PubMed Web of Science ®Google Scholar
• Rennels M, King J Jr, Ryall R, Papa T, Froeschle J. Dosage escalation, safety and immunogenicity study of four dosages of a tetravalent meninogococcal polysaccharide diphtheria toxoid conjugate vaccine in infants. Pediatr. Infect. Dis. J.23(5), 429–435 (2004).
   PubMed Web of Science ®Google Scholar
• Pace D. Quadrivalent meningococcal ACYW-135 glycoconjugate vaccine for broader protection from infancy. Expert Rev. Vaccines8(5), 529–542 (2009).
   PubMed Web of Science ®Google Scholar
• Jackson LA, Baxter R, Reisinger K et al. Phase III comparison of an investigational quadrivalent meningococcal conjugate vaccine with the licensed meningococcal ACWY conjugate vaccine in adolescents. Clin. Infect. Dis.49(1), e1–e10 (2009).
   PubMed Web of Science ®Google Scholar
• Knuf M, Kieninger-Baum D, Habermehl P et al. A dose-range study assessing immunogenicity and safety of one dose of a new candidate meningococcal serogroups A, C, W-135, Y tetanus toxoid conjugate (MenACWY-TT) vaccine administered in the second year of life and in young children. Vaccine28(3), 744–753 (2010).
   PubMed Web of Science ®Google Scholar
• Feikin DR, Elie CM, Goetz MB et al. Randomized trial of the quantitative and functional antibody responses to a 7-valent pneumococcal conjugate vaccine and/or 23-valent polysaccharide vaccine among HIV-infected adults. Vaccine20(3–4), 545–553 (2001).
   PubMed Web of Science ®Google Scholar
• Poolman J, Kriz P, Feron C et al. Pneumococcal serotype 3 otitis media, limited effect of polysaccharide conjugate immunisation and strain characteristics. Vaccine27(24), 3213–3222 (2009).
   PubMed Web of Science ®Google Scholar
• Prymula R, Peeters P, Chrobok V et al. Pneumococcal capsular polysaccharides conjugated to protein D for prevention of acute otitis media caused by both Streptococcus pneumoniae and non-typable Haemophilus influenzae: a randomised double-blind efficacy study. Lancet367(9512), 740–748 (2006).
   PubMed Web of Science ®Google Scholar
• Nurkka A, Joensuu J, Henckaerts I et al. Immunogenicity and safety of the eleven valent pneumococcal polysaccharide-PD conjugate vaccine in infants. Pediatr. Infect. Dis. J23(11), 1008–1014 (2004).
   PubMed Web of Science ®Google Scholar
• Grimprel E, Scott D, Laudat F, Baker S, Gruber W. Safety and immunogenicity of a 13-valent pneumococcal conjugate vaccine given with routine pediatric vaccination to healthy infants in France. Presented at: 48th Annual ICAAC. Washington DC, USA, 25–28 October 2008.
   Google Scholar
• Örtqvist Å, Henckaerts I, Hedlund J, Poolman J. Non-response to specific serotypes likely cause for failure to 23-valent pneumococcal polysaccharide vaccine in the elderly. Vaccine25(13), 2445–2450 (2007).
   PubMed Web of Science ®Google Scholar
• Edwards EA, Devine LF, Sengbusch GH, Ward HW. Immunological investigations of meningococcal disease. III. Brevity of group C acquisition prior to disease occurrence. Scand. J. Infect. Dis.9(2), 105–110 (1977).
   PubMed Web of Science ®Google Scholar
• Andersen J, Berthelsen L, Jensen BB, Lind I. Surveillance of cases of meningococcal disease associated with military recruits studied for meningococcal carriage. Scand. J. Infect. Dis.32(5), 527–531 (2000).
   PubMedGoogle Scholar
• Auckland C, Gray S, Borrow R et al. Clinical and immunologic risk factors for meningococcal C conjugate vaccine failure in the United Kingdom. J. Infect. Dis.194(12), 1745–1752 (2006).
   PubMed Web of Science ®Google Scholar
• Osterholm MT, Rambeck JH, White KE et al. Lack of efficacy of Haemophilus b polysaccharide vaccine in Minnesota. JAMA260(10), 1423–1428 (1988).
   PubMedGoogle Scholar
• Granoff DM, Osterholm MT. Safety and efficacy of Haemophilus influenzae type b polysaccharide vaccine. Pediatrics80(4), 590–592 (1987).
   PubMedGoogle Scholar
• McVernon J, Johnson PD, Pollard A, Slack MP, Moxon ER. Immunologic memory in Haemophilus influenzae type b conjugate vaccine failure. Arch. Dis. Child.88(5), 379–383 (2003).
   PubMed Web of Science ®Google Scholar
• Clutterbuck EA, Salt P, Oh S, Marchant A, Beverley P, Pollard AJ. The kinetics and phenotype of the human B-cell response following immunization with a heptavalent pneumococcal-CRM conjugate vaccine. Immunology119(3), 328–337 (2006).
   PubMed Web of Science ®Google Scholar
• Snape MD, Pollard AJ. Meningococcal polysaccharide-protein conjugate vaccines. Lancet Infect. Dis.5(1), 21–30 (2005).
   PubMed Web of Science ®Google Scholar
• Kelly DF, Snape MD, Perrett KP et al. Plasma and memory B-cell kinetics in infants following a primary schedule of CRM197-conjugated serogroup C meningococcal polysaccharide vaccine. Immunology127(1), 134–143 (2009).
   PubMed Web of Science ®Google Scholar
• Blanchard-Rohner G, Pulickal AS, Jol-van der Zijde CM, Snape MD, Pollard AJ. Appearance of peripheral blood plasma cells and memory B cells in a primary and secondary immune response in humans. Blood114(24), 4998–5002 (2009).
   PubMedGoogle Scholar
• Pollard AJ, Perrett KP, Beverley PC. Maintaining protection against invasive bacteria with protein–polysaccharide conjugate vaccines. Nat. Rev. Immunol.9(3), 213–220 (2009).
   PubMed Web of Science ®Google Scholar
• Daum RS, Sood SK, Osterholm MT et al. Decline in serum antibody to the capsule of Haemophilus influenzae type b in the immediate postimmunization period. J. Pediatr.114(5), 742–747 (1989).
   PubMedGoogle Scholar
• O’Brien KL, Moïsi J, Romero-Steiner S et al. Pneumococcal antibodies in a child with type 14 pneumococcal conjugate vaccine failure. Vaccine27(12), 1863–1868 (2009).
   PubMedGoogle Scholar
• Joint Committee on Vaccination and Immunisation. Pneumococcal Sub-group. Minutes of the Pneumococcal subgroup on Tuesday 15th January 2009. Department of Health. Joint Committee on Vaccination and Immunisation. Pneumococcal Sub-group, London, UK (2009).
   Google Scholar
• World Health Organization. Recommendations to Assure the Quality, Safety and Efficacy of Group A Meningococcal Conjugate Vaccines. WHO Press, Geneva, Switzerland (2006).
   Google Scholar
• De Wals P. Meningococcal C vaccines: the Canadian experience. Pediatr. Infect. Dis. J.23(12 Suppl.), S280–S284 (2004).
   PubMedGoogle Scholar
• Soriano-Gabarró M, Toé L, Tiendrebeogo SR et al. Effectiveness of a trivalent serogroup A/C/W135 meningococcal polysaccharide vaccine in Burkina Faso, 2003. Vaccine25(Suppl. 1), A92–A96 (2007).
   PubMed Web of Science ®Google Scholar
• Dagan R, Poolman J, Siegrist CA. Glycoconjugate vaccines and immune interference: a review. Vaccine28(34), 5513–5523 (2010).
   PubMed Web of Science ®Google Scholar
• Schuerman L, Prymula R, Chrobok V, Dieussaert I, Poolman J. Kinetics of the immune response following pneumococcal PD conjugate vaccination. Vaccine25(11), 1953–1961 (2007).
   PubMed Web of Science ®Google Scholar
• Kieninger DM, Kueper K, Steul K et al. Safety, tolerability, and immunologic noninferiority of a 13-valent pneumococcal conjugate vaccine compared to a 7-valent pneumococcal conjugate vaccine given with routine pediatric vaccinations in Germany. Vaccine28(25), 4192–4203 (2010).
   PubMed Web of Science ®Google Scholar
• Bryant KA, Block SL, Baker SA et al. Safety and immunogenicity of a 13-valent pneumococcal conjugate vaccine. Pediatrics125(5), 866–875 (2010).
   PubMed Web of Science ®Google Scholar
• Bryant KA, Block SL, Scott DA. Safety and immunogenicity of a 4th dose of 13-valent pneumococcal conjugate vaccine in healthy toddlers. Presented at: 26th Annual Meeting of the European Society for Paediatric Infectious Diseases. Graz, Austria, 13–17 May 2008.
   Google Scholar
• Gadzinowski J, Daniels ED, Giardina P et al. Safety and immunogenicity of a 13-valent pneumococcal conjugate vaccine manufactured with and without polysorbate 80 in healthy infants given a 2, 3, 4 and 12 months of age. Presented at: 27th Annual Meeting of the European Society for Paediatric Infectious Diseases. Brussels, Belgium, 9–13 June 2009.
   Google Scholar
• Diez-Domingo J, Gurtman A, Bernaola E et al. Safety and immunogenicity of 13-valent pneumococcal conjugate vaccine in healthy infants and toddlers receiving routine vaccinations in Spain. Presented at: 27th Annual Meeting of the European Society for Paediatric Infectious Diseases. Brussels, Belgium, 9–13 June 2009.
   Google Scholar
• Esposito S, Tansey S, Thompson A et al. Safety and immunogenicity of a 13-valent pneumococcal conjugate vaccine compared to those of a 7-valent pneumococcal conjugate vaccine given as a three-dose series with routine vaccines in healthy infants and toddlers. Clin. Vaccine Immunol.17(6), 1017–1026 (2010).
   PubMed Web of Science ®Google Scholar
• Grimprel E, Laudat F, Baker SA et al. Safety and immunogenicity of a 13–valent pneumococcal conjugate vaccine given with routine pediatric vaccination to healthy infants in France. Presented at: 27th Annual Meeting of the European Society for Paediatric Infectious Diseases. Brussels, Belgium, 9–13 June 2009.
   Google Scholar
• Nurkka A, Ahman H, Yaich M, Eskola J, Käyhty H. Serum and salivary anti-capsular antibodies in infants and children vaccinated with octavalent pneumococcal conjugate vaccines, PncD and PncT. Vaccine20(1–2), 194–201 (2002).
   Web of Science ®Google Scholar
• Puumalainen T, Dagan R, Wuorimaa T et al. Greater antibody responses to an eleven valent mixed carrier diphtheria- or tetanus-conjugated pneumococcal vaccine in Filipino than in Finnish or Israeli infants. Pediatr. Infect. Dis. J.22(2), 141–149 (2003).
   PubMed Web of Science ®Google Scholar
• Dagan R, Käyhty H, Wuorimaa T et al. Tolerability and immunogenicity of an eleven valent mixed carrier Streptococcus pneumoniae capsular polysaccharide–diphtheria toxoid or tetanus protein conjugate vaccine in Finnish and Israeli infants. Pediatr. Infect. Dis. J.23(2), 91–98 (2004).
   PubMed Web of Science ®Google Scholar
• Dagan R, Goldblatt D, Maleckar JR, Yaïch M, Eskola J. Reduction of antibody response to an 11-valent pneumococcal vaccine coadministered with a vaccine containing acellular pertussis components. Infect. Immun.72(9), 5383–5391 (2004).
   PubMed Web of Science ®Google Scholar